Program
efitazanamivir alfa
A development code. Also written as “CD388 Injection”, “MK-1406” and “MK-1406 Injection”.
In Merck's pipeline, MK-1406 is an investigational drug-Fc conjugate that consists of a neuraminidase inhibitor linked to an Fc fragment of a human antibody.
. Its studies are mostly in Influenza, Human, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 84 open or running | phase 3since Aug 29, 2025 | Mar 8, 2022 | Dec 31, 2026phase 1 · NCT07300085 |
- Named in Merck’s own pipeline as
efitazanamivir alfa (MK-1406)
, phase 3, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Johnson & Johnson.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2022First study: phase 1 study in HealthyFirst studyNCT05285137 · 77 enrolled · United States
- Aug 29, 2022Phase 2 study in Influenza, HumanNCT05523089 · 59 enrolled · United Kingdom
- Nov 9, 2022Phase 1 study in HealthyNCT05619536 · 28 enrolled · United States
- Sep 20, 2024Phase 2 study in Influenza, HumanNCT06609460 · 5,071 enrolled · United States, United Kingdom
- Aug 29, 2025Phase 3 study in Influenza, HumanNCT07159763 · 10,000 planned · United States, Argentina, Australia and more
- Nov 6, 2025Phase 2 study in Influenza, HumanNCT07225959 · 400 enrolled · United States, United Kingdom
- Dec 10, 2025Phase 1 study in Influenza, HumanNCT07300085 · 710 planned · United States
- Jul 29, 2026Phase 1 study in HealthyNCT07743151 · 400 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Influenza, HumanNCT07300085
- Feb 5, 2027Primary completion: phase 1 study in HealthyNCT07743151
- Jul 2, 2027Primary completion: phase 3 study in Influenza, HumanNCT07159763
- Jul 31, 2027Primary completion: phase 2 study in Influenza, HumanNCT07225959
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“MK-1406 is an investigational drug-Fc conjugate that consists of a neuraminidase inhibitor linked to an Fc fragment of a human antibody.”the company's pipeline, read by Claude · source
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07743151Healthy · United States | 1 | Recruiting | Feb 5, 2027 | 400 |
| NCT07300085Influenza, Human · United States | 1 | Recruiting | Dec 31, 2026 | 710 |
| NCT07225959Influenza, Human · United States, United Kingdom | 2 | Active, not recruiting | Jul 31, 2027 | 400 |
| NCT07159763Influenza, Human · United States, Argentina, Australia and more | 3 | Recruiting | Jul 2, 2027 | 10,000 |
| NCT06609460Influenza, Human · United States, United Kingdom | 2 | Completed | Oct 9, 2025 | 5,071 |
| NCT05619536Healthy · United States | 1 | Completed | Jul 14, 2023 | 28 |
| NCT05523089Influenza, Human · United Kingdom | 2 | Completed | Jul 17, 2023 | 59 |
| NCT05285137Healthy · United States | 1 | Completed | Oct 27, 2023 | 77 |
How it is read
Names in the registry
- “CD388 Injection”, 3 entries
- “MK-1406”, 2 entries
- “MK-1406 Injection”, 2 entries
- “CD388”, 1 entry
Codes read as this program: MK1406.
Conditions, from the studies’ own filings
- Influenza, Human, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.